Literature DB >> 27604906

Quantitative Proteomic Profiling Reveals That Diverse Metabolic Pathways Are Influenced by Melatonin in an in Vivo Model of Ovarian Carcinoma.

Luiz Gustavo A Chuffa1, Luiz Antonio Lupi Júnior1, Fábio R F Seiva2, Marcelo Martinez3, Raquel F Domeniconi1, Patricia Fernanda F Pinheiro1, Lucilene D Dos Santos4, Francisco Eduardo Martinez1.   

Abstract

To obtain more information into the molecular mechanisms underlying ovarian cancer (OC), we proposed a comparative proteomic analysis in animals receiving long-term melatonin as therapy or only vehicle using multidimensional protein identification combined with mass spectrometry. To induce tumor, a single dose of 100 μg 7,12-dimethylbenz(a)anthracene (DMBA) dissolved in 10 μL of sesame oil was injected under the left ovarian bursa of 20 Fischer 344 rats. The right ovaries were injected with sesame oil only. After tumors were developed, half of the animals received intraperitoneal administration of melatonin (200 μg/100g body weight/day) for 60 days. Melatonin therapy promoted down-regulation in numerous proteins involved in OC signaling pathways. The most significant portion of these proteins are involved in several metabolic processes, mainly those associated with mitochondrial systems, generation of metabolites and energy, hypoxia-inducible factor-1 signaling, antigen processing and presentation, endoplasmic reticulum stress-associated pathways, and cancer-related proteoglycans. A small number of proteins that were overexpressed by melatonin therapy included ATP synthase subunit β, fatty acid-binding protein, and 10-kDa heat shock protein. Taken together, our findings suggest that melatonin therapy efficiently modulated important signaling pathways involved in OC, and these proteins might be further targets that should be explored in new therapeutic opportunities for OC.

Entities:  

Keywords:  ER stress; energy; mass spectrometry; melatonin; mitochondrial metabolism; ovarian cancer

Mesh:

Substances:

Year:  2016        PMID: 27604906     DOI: 10.1021/acs.jproteome.6b00713

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  15 in total

Review 1.  Melatonin in Cancer Treatment: Current Knowledge and Future Opportunities.

Authors:  Wamidh H Talib; Ahmad Riyad Alsayed; Alaa Abuawad; Safa Daoud; Asma Ismail Mahmod
Journal:  Molecules       Date:  2021-04-25       Impact factor: 4.411

Review 2.  Melatonin, a Full Service Anti-Cancer Agent: Inhibition of Initiation, Progression and Metastasis.

Authors:  Russel J Reiter; Sergio A Rosales-Corral; Dun-Xian Tan; Dario Acuna-Castroviejo; Lilan Qin; Shun-Fa Yang; Kexin Xu
Journal:  Int J Mol Sci       Date:  2017-04-17       Impact factor: 5.923

3.  Platinum-containing compound platinum pyrithione suppresses ovarian tumor proliferation through proteasome inhibition.

Authors:  Hongbiao Huang; Ni Liu; Yuning Liao; Ningning Liu; Jianyu Cai; Xiaohong Xia; Zhiqiang Guo; Yanling Li; Qirong Wen; Qi Yin; Yan Liu; Qingxia Wu; Dhivya Rajakumar; Xiujie Sheng; Jinbao Liu
Journal:  J Exp Clin Cancer Res       Date:  2017-06-15

4.  Melatonin Reduces Angiogenesis in Serous Papillary Ovarian Carcinoma of Ethanol-Preferring Rats.

Authors:  Yohan Ricci Zonta; Marcelo Martinez; Isabel Cristina C Camargo; Raquel F Domeniconi; Luiz Antonio Lupi Júnior; Patricia Fernanda F Pinheiro; Russel J Reiter; Francisco Eduardo Martinez; Luiz Gustavo A Chuffa
Journal:  Int J Mol Sci       Date:  2017-04-11       Impact factor: 5.923

Review 5.  Melatonin and Mesenchymal Stem Cells as a Key for Functional Integrity for Liver Cancer Treatment.

Authors:  Ehab Kotb Elmahallawy; Yasser Mohamed; Walied Abdo; Tokuma Yanai
Journal:  Int J Mol Sci       Date:  2020-06-25       Impact factor: 5.923

6.  Progesterone at high doses reduces the growth of U87 and A172 glioblastoma cells: Proteomic changes regarding metabolism and immunity.

Authors:  Meric A Altinoz; Yasemin Ucal; Muazzez C Yilmaz; İrem Kiris; Ozan Ozisik; Ugur Sezerman; Aysel Ozpinar; İlhan Elmaci
Journal:  Cancer Med       Date:  2020-06-26       Impact factor: 4.452

7.  Melatonin and Docosahexaenoic Acid Decrease Proliferation of PNT1A Prostate Benign Cells via Modulation of Mitochondrial Bioenergetics and ROS Production.

Authors:  Guilherme H Tamarindo; Daniele L Ribeiro; Marina G Gobbo; Luiz H A Guerra; Paula Rahal; Sebastião R Taboga; Fernanda R Gadelha; Rejane M Góes
Journal:  Oxid Med Cell Longev       Date:  2019-01-09       Impact factor: 6.543

8.  Overcoming platinum-acquired resistance in ovarian cancer patient-derived xenografts.

Authors:  Francesca Ricci; Laura Brunelli; Roberta Affatato; Rosaria Chilà; Martina Verza; Stefano Indraccolo; Francesca Falcetta; Maddalena Fratelli; Robert Fruscio; Roberta Pastorelli; Giovanna Damia
Journal:  Ther Adv Med Oncol       Date:  2019-06-24       Impact factor: 8.168

9.  P-MAPA immunotherapy potentiates the effect of cisplatin on serous ovarian carcinoma through targeting TLR4 signaling.

Authors:  Luiz Gustavo de Almeida Chuffa; Grazielle de Moura Ferreira; Luiz Antonio Lupi; Iseu da Silva Nunes; Wagner José Fávaro
Journal:  J Ovarian Res       Date:  2018-01-17       Impact factor: 4.234

Review 10.  Melatonin: An Anti-Tumor Agent in Hormone-Dependent Cancers.

Authors:  Javier Menéndez-Menéndez; Carlos Martínez-Campa
Journal:  Int J Endocrinol       Date:  2018-10-02       Impact factor: 3.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.